Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

D
W-011
Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections

Favorite
M-065
Decoding Mean Viral Load in RSV Human Challenge Studies

Favorite
T-092
Delineate: a Literature Co-Pilot for Quantitative Systems Pharmacology

Favorite
W-139
Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose

Favorite
M-003
Determining an Appropriate Fosfomycin Dosing Regimen in Pneumonia Patients by Utilizing minimal PBPK Modeling and Target Attainment Analysis

Favorite
M-031
Development and application of a mechanistic model for Alzheimer’s Disease

Favorite
M-046
Development and Application of Inavolisib Physiologically-based Pharmacokinetic (PBPK) Model for Drug-drug Interaction (DDI) Assessment

Favorite
W-028
Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population

Favorite
W-038
Development of a Physiologically-Based Pharmacokinetic (PBPK) Model for Caffeine in Pregnancy: Evaluating Neonatal Transfer

Favorite
T-119
Development of a Population Pharmacokinetic Model for Ganciclovir to Assess the Renal Impairment Impact in Chinese Patients

Favorite
W-101
Development of a Population PK model for an inhaled drug

Favorite
M-013
Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.

Favorite
M-080
Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV

Favorite
T-086
Development of a Whole-Body Physiologically Based Pharmacokinetics (PBPK) Model for Predicting Dynamics of mRNA and Protein for LNP-Encapsulated mRNA Therapeutics

Favorite
W-053
Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution

Favorite
W-004
Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1

Favorite
T-009
Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer

Favorite
T-130
Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients

Favorite
M-001
Direct and Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis

Favorite
W-141
Disease progression modeling of myositis from real-world data

Favorite
M-049
Disease Progression Modeling of Stargardt’s disease

Favorite
M-020
Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy

Favorite
W-068
Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation

Favorite
W-002
Dual Physiologically-based Pharmacokinetics Models of Nano-Liposomal (Nal-IRI) and Non-Liposomal Irinotecan in Ewing’s Family Tumor Xenograft

Favorite
W-122
Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4

Favorite